Glioblastoma in elderly patients: Safety and efficacy of adjuvant radiotherapy with concomitant temozolomide

F. Fiorica, M. Berretta, C. Colosimo, A. Stefanelli, S. Ursino, E. Zanet, T. Palmucci, D. Maugeri, M. Malaguarnera, S. Palmucci, M. Grasso, U. Tirelli, F. Cartei

Research output: Contribution to journalArticlepeer-review


The aim of this study was to evaluate the impact of radiotherapy plus concomitant and adjuvant temozolomide (TMZ), in terms of feasibility and activity, in elderly patients with glioblastoma. From January 2002 to December 2007, 42 consecutive patients with glioblastoma (27 men and 15 women) aged 65 years or more (median age 71.3 years), received radiotherapy plus concomitant and adjuvant TMZ. Nineteen patients (45.2%) had a Karnofsky index ≥80. Thirty-six patients (85.8%) underwent complete or subtotal resection, while 6 patients (14.2%) were only biopsied. All patients received adjuvant radiotherapy within 4 weeks from surgery. Twenty-two patients (54.8%) underwent adjuvant TMZ. Early discontinuation of concomitant TMZ program due to toxicity was observed in 8 patients. Considered variables were: age, Karnofsky index, surgery versus no surgery, radiation dose, and chemotherapy. At a median follow-up of 10.2 months, the 6- and 12-month overall survival rates were 81.9% and 27.8%, respectively. There was a significantly better survival for patients with a performance status according to Karnofsky >80 (p

Original languageEnglish
Pages (from-to)31-35
Number of pages5
JournalArchives of Gerontology and Geriatrics
Issue number1
Publication statusPublished - Jul 2010


  • Elderly patients with glioblastoma
  • Lung cancer
  • Radiotherapy
  • Temozolomide therapy

ASJC Scopus subject areas

  • Ageing
  • Geriatrics and Gerontology
  • Health(social science)
  • Gerontology


Dive into the research topics of 'Glioblastoma in elderly patients: Safety and efficacy of adjuvant radiotherapy with concomitant temozolomide'. Together they form a unique fingerprint.

Cite this